Currently his lab is collaborating with biologists at Emory University to protect mitochondria from toxic
nucleoside reverse transcriptase inhibitors.
Not exact matches
All but one fall into one of three categories — either
nucleoside or nonnucleoside
reverse transcriptase inhibitors or protease inhibitors — based on the part of the virus they target.
Current anti-HBV therapeutics are interferon and
nucleoside analog inhibitors of HBV
reverse transcriptase (Pol).